Gastric cancer management: Kinases as a target therapy

Clinical and Experimental Pharmacology and Physiology - Tập 44 Số 6 - Trang 613-622 - 2017
Batoul Farran1, Susanne Müller2, Raquel Carvalho Montenegro3
1Department of Structural and Molecular Biology, University College London, London, UK
2Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Frankfurt am Main, DE, Germany
3Drug Research and Development Center, Federal University of Ceará, Fortaleza, CE, Brazil

Tóm tắt

SummaryThe molecular diagnostics revolution has reshaped the practice of oncology by facilitating the identification of genetic, epigenetic and proteomic modifications correlated with cancer, thus delineating ‘oncomaps’ for various cancer types. These advances have enhanced our understanding of gastric cancer, one of the most fatal diseases worldwide, and culminated in the approval of novel molecular therapies such as trastuzumab. Gastric tumours display recurrent aberrations in key kinase oncogenes such as Her2, epidermal growth factor receptor (EGFR), PI3K, mTOR or c‐Met, suggesting that these receptors are amenable to inhibition using specific drug agents. In this review, we examine the mutational landscape of gastric cancer, the use of kinase inhibitors as targeted therapies in gastric tumours and the clinical trials underway for novel inhibitors, highlighting successes, failures and future directions.

Từ khóa


Tài liệu tham khảo

10.1002/ijc.29210

10.3322/caac.21262

Chan BA, 2016, Improving Outcomes in Resectable Gastric Cancer: A Review of Current and Future Strategies, Oncology (Williston Park), 30, 635

Chan BA, 2015, Targeted therapy for non‐small cell lung cancer: current standards and the promise of the future, Transl Lung Cancer Res, 4, 36

10.1039/C5AN01863C

10.1007/s00018-006-6202-8

10.1016/j.tips.2014.09.007

10.1038/nature13480

10.1016/j.critrevonc.2016.02.007

10.1007/s12253-016-0066-5

10.18632/oncotarget.4990

10.3748/wjg.v22.i3.1160

10.3748/wjg.v22.i20.4812

10.1016/j.tips.2015.04.005

10.1007/s00018-005-5205-1

10.1016/S0021-9258(19)34204-8

10.1038/260170a0

10.1038/nrd839

Gerber DE, 2008, Targeted therapies: a new generation of cancer treatments, Am Fam Physician, 77, 311

10.1200/JCO.2004.10.182

Mendelsohn J, 2000, Blockade of receptors for growth factors: an anticancer therapy–the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture, Clin Cancer Res, 6, 747

10.1016/j.critrevonc.2004.10.011

10.1371/journal.pone.0163366

10.1200/JCO.1999.17.9.2639

10.1056/NEJMra043186

10.1016/S1470-2045(13)70130-X

10.1158/1078-0432.CCR-13-1212

10.1053/sonc.2002.34056

10.1007/s10549-016-3751-x

10.1007/s10549-016-3750-y

10.1016/S1470-2045(10)70070-X

Harada K, 2016, Global chemotherapy development for gastric cancer, Gastric Cancer, 20, 92

10.1200/JCO.2000.18.14.2648

10.2165/11205900-000000000-00000

10.1016/S0140-6736(10)61121-X

10.1556/650.2016.30535

10.1177/1078155216655474

10.1038/bjc.2016.293

10.1016/S1470-2045(14)70420-6

10.1200/JCO.2015.62.6598

10.1200/JCO.2013.53.6136

10.1038/bjc.2014.356

10.1016/S1470-2045(13)70102-5

10.3748/wjg.v20.i14.3905

10.1016/S1470-2045(13)70096-2

10.1007/s10120-014-0420-9

10.1200/JCO.2006.07.1316

10.1200/JCO.2011.36.2236

10.1016/j.canlet.2016.01.014

10.1200/JCO.2015.63.5995

10.1038/nrclinonc.2016.53

10.1200/JCO.2016.68.6931

10.1038/bjc.2012.100

10.1200/JCO.2009.27.7988

10.3892/ijmm.2016.2620

10.1038/bjc.2013.802

10.1158/1078-0432.CCR-12-3898

10.1136/gutjnl-2011-301839

10.1158/1535-7163.MCT-11-0450

10.1016/j.coph.2015.05.016

10.3389/fphys.2016.00168

10.1002/ijc.22442

10.1002/cncr.29363

10.1186/bcr3577

10.1158/1078-0432.CCR-12-0714

10.1016/S1470-2045(14)71159-3

10.1200/JCO.2012.48.3552

10.1158/1078-0432.CCR-11-2381

10.1016/j.canlet.2015.05.028

10.1371/journal.pone.0054014

10.1007/s10637-013-0057-2

10.1126/science.342.6165.1432

10.4236/jct.2013.45116

10.1155/2011/437348

2013, PD‐1 inhibitor becomes “breakthrough therapy”, Cancer Discov, 3, OF14, 10.1158/2159-8290.CD-NB2013-074

10.1358/dot.2015.51.1.2250387

10.1158/1078‐0432.CCR‐16‐0714

Raedler LA, 2015, Opdivo (Nivolumab): Second PD‐1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma, Am Health Drug Benefits, 8, 180

Beaver JA, 2017, FDA Approval of Nivolumab for the First‐Line Treatment of Patients with BRAFV600 Wild‐Type Unresectable or Metastatic Melanoma, Clin Cancer Res, 33, 749

10.1155/2015/308574

10.2217/imt.16.10

10.1016/j.critrevonc.2015.08.015

10.1080/03007995.2017.1279132

10.1016/S1470-2045(16)00175-3

10.18632/oncotarget.14825

10.21037/jgo.2016.08.06

10.1186/s12885-016-2736-9

10.1200/JCO.2013.48.8585

Jhawer M, 2009, Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study, J Clin Oncol, 27, 4502, 10.1200/jco.2009.27.15_suppl.4502

10.1200/JCO.2014.60.0320

10.1007/s12094-014-1258-7

Thông tin
Thông tin xuất bản

Clinical and Experimental Pharmacology and Physiology

Tập 44 Số 6

613-622

Thông tin tác giả